Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.
Foster and Thrive Gentle Laxative Bisacodyl 10 mg/2000mg Suppository — NDC 70677-1091-1 (Billing 70677-1091-01)
by Strategic Sourcing Services LLC · 2 BLISTER PACK in 1 CARTON / 40 mg in 1 BLISTER PACK
This is a package of Foster and Thrive Gentle Laxative Bisacodyl 10 mg/2000mg Suppository from Strategic Sourcing Services LLC, marketed since Jan 2023 and currently FDA-listed; retail pharmacies pay about $0.3197 per unit (NADAC). It is this product's only package size.
NDC 70677-1091-01
🏷️ FDA NDC (as labeled)
70677-1091-1
billing pads the package segment with a zero
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
NDC database record
One package, one record: these facts belong to NDC 70677-1091-1 alone.
- Record
- FDA NDC Directory package listing · Human OTC drug
- Code segments
- 70677 labeler · 1091 product · 1 package
- Package marketed since
- Dec 18, 2024
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC)
- 0052569142608
- Medicaid fills, this package
- 207 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
70677-1091-1
Product NDC
70677-1091
11-digit billing NDC
70677109101
NCPDP billing unit
EA — each (per item)
RxCUI
198509
UNII
10X0709Y6I
UPC
0052569142608
Application #
M007
SPL Set ID
d03c2c42-d9d9-4b4b-a6ae-31d99425a228
Established class (EPC)
Stimulant Laxative
Physiologic effect
Increased Large Intestinal Motility; Stimulation Large Intestine Fluid/Electrolyte Secretion
DEA schedule
Non-controlled
Marketing category
OTC MONOGRAPH DRUG
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2023-01-27
Route
RECTAL
Dosage form
SUPPOSITORY
Substance
BISACODYL
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
GPI-14
46200010005205
GCN Seq No
002944
GCN
08731
HICL code
001301
Ingredient (HICL)
Bisacodyl
HIC1 code
Q
Therapeutic class — broad (HIC1)
Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code
Q3
Therapeutic class — intermediate (HIC2)
Anal-Rectal Preparations
HIC3 code
Q3S
Therapeutic class — specific (HIC3)
Laxatives, Local/Rectal
AHFS code
56:12.00.00
AHFS class
Cathartics And Laxatives
FDB label name
FT GENTLE LAXATIVE 10 MG SUPP
FDB brand name
Gentle Laxative
Legend status
O — Over-the-counter (OTC) drug or device
Quick answers
- GSN (GCN sequence number): 002944
- GCN: 08731
- GPI-14 (Medi-Span): 46200010005205
- HICL (First Databank): 001301
- AHFS class code: 56:12.00.00
- RxCUI (RxNorm): 198509
Why two NDCs?
The FDA registers this code as 70677-1091-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70677-1091-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 8, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Stimulant Laxative class.
Pharmacologic class
Stimulant Laxative
Drug family (ATC)
Contact laxatives, Enemas
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
- RxClass (NLM) · catalog refreshed Oct 8, 2026
Clinical
Label name FT GENTLE LAXATIVE 10 MG SUPP Ingredient Bisacodyl
📖 What it is MedlinePlus · NLM
Rectal bisacodyl is used on a short-term basis to treat constipation. It also is used to empty the bowels before surgery and certain medical procedures. Bisacodyl is in a class of medications called stimulant laxatives. It works by increasing activity of the intestines to cause a bowel movement.
Read the full MedlinePlus article ↗📗 Our plain-language guide HelloPharmacist
- It relieves occasional constipation and irregularity. The Fleet enema is also used for fecal impaction and to clear residue after a barium test. It is meant for short-term use.
- It depends on the form. Tablets usually work in 6 to 12 hours. Suppositories usually work in 15 minutes to 1 hour. The Fleet enema usually works in 5 to 20 minutes.
- Not right away. Wait at least 1 hour after an antacid or milk before taking tablets. Swallow tablets whole with water and do not chew or crush them.
- Can I take the tablets with an antacid or milk?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Bisacodyl — tap one for details:
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
💬 Questions about Bisacodyl?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.320 | $0.64 / 2 blister packs |
| Medicaid paysCMS SDUD · 12 mo | $0.8097 | $1.62 / 2 blister packs |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
NADAC price history (per ea) — tap or hover for the price & month
▲ Up 3% over the last 13 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file · file of Oct 7, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 70677-1091-01 You're viewing this Main listing | 2 BLISTER PACK in 1 CARTON / 40 mg in 1 BLISTER PACK | 2023-01-27 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Bisacodyl 10 mg 00574-7050-12 | Padagis | 12 suppositories | $0.320 | — | Availability likely | — |
| Bisacodyl 10 mg 00904-7142-12 | Major | 12 suppositories | $0.320 | — | Availability likely | — |
| Good Neighbor Pharmacy Gentle Laxative 10 mg/2000mg 46122-0608-51 | AmerisourceBergen | 40 mg | $0.320 | — | Availability likely | — |
| Bisacodyl 10 mg 57237-0327-03 | Rising | 30 suppositories | $0.320 | — | Availability likely | — |
| Proctozone-B 10 mg 57237-0337-03 | Rising | 30 suppositories | $0.320 | — | Availability likely | — |
| Bisacodyl 10 mg 70000-0573-01 | Cardinal | 4 suppositories | $0.320 | — | Availability likely | — |
| Foster and Thrive Gentle Laxative 10 mg/2000mgthis 70677-1091-01 | Strategic | 40 mg | $0.320 | — | Availability likely | — |
| Walgreens Gentle Laxative 10 mg 00363-0466-04 | Walgreens | 40 mg | — | — | FDA listed | — |
| Walgreens Gentle Laxative 10 mg 00363-0468-04 | Walgreens | 4 suppositories | — | — | FDA listed | — |
| Rite-Aid Gentle Laxative 10 mg 11822-4890-05 | RITE | 8 suppositories | — | — | FDA listed | — |
| Gentle Laxative Bisacodyl 10 mg 13709-0321-01 | NeilMed | 30 capsules | — | — | FDA listed | — |
| Bisacodyl Laxative 10 mg/1.8g 13709-0328-01 | Neilmed | 1.8 g | — | — | FDA listed | — |
| HEB Gentle Laxative 10 mg/2000mg 37808-0877-08 | H | 40 mg | — | — | FDA listed | — |
| Dulcolax Laxative 10 mg 41167-0210-01 | Chattem, | 4 suppositories | — | — | FDA listed | — |
| Meijer Gentle Laxative 10 mg/2000mg 41250-0665-04 | Meijer | 40 mg | — | — | FDA listed | — |
| Discount Drugmart Gentle Laxative 10 mg/2000mg 53943-0805-08 | Discount | 40 mg | — | — | FDA listed | — |
| Dollar General Gentle Laxative 10 mg/2000mg 55910-0457-04 | Dolgencorp, | 40 mg | — | — | FDA listed | — |
| Bisacodyl 10 mg 57896-0443-01 | GERI-CARE | 100 suppositories | — | — | FDA listed | — |
| Stratuscare Bisacodyl 10 mg 58980-0415-04 | Stratus | 4 suppositories | — | — | FDA listed | — |
| CVS Gentle Laxative 10 mg 59779-0107-09 | CVS | 8 suppositories | — | — | FDA listed | — |
| Bisacodyl 10 mg 68016-0084-08 | Pharmacy | 8 suppositories | — | — | FDA listed | — |
| Bisacodyl 10 mg 69842-0816-04 | CVS | 4 suppositories | — | — | FDA listed | — |
| Laxative 10 mg 70795-1010-01 | GRAXCELL | 100 suppositories | — | — | FDA listed | — |
| OneLAX 10 mg 71399-8460-02 | AKRON | 12 suppositories | — | — | FDA listed | — |
| Conlax 10 mg 72701-0102-04 | Bliss | 4 suppositories | — | — | FDA listed | — |
| Bisacodyl 10 mg 82568-0028-02 | AARNA | 12 suppositories | — | — | FDA listed | — |
| Bisacodyl 10 mg 83720-0550-25 | Oncor | 12 suppositories | — | — | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Oct 7, 2026
Availability & generic status
🏛️
2023
On the market since
Jan 2023
📍
2026
Currently FDA-listed
3 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Oct 3, 2026
What it looks like
Color
white
ShapeBullet
Size34 mm
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Bisacodyl inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 8334LX7S21
A solid fat derived from animal or vegetable sources, used as a coating agent and lubricant to help pills slide smoothly during manufacturing and protect the medicine from moisture and air.
1 inactive ingredient listed in the exact product block matched to this NDC.
The official label also stateshydrogenated vegetable oil
Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerStrategic Sourcing Services LLC
FDA applicationM007 (OTC MONOGRAPH DRUG)
Labeler code70677
First marketedJan 2023
Product typeHuman Otc Drug
Portfolio316 products on file
More NDCs from Strategic Sourcing Services LLC labeler code 70677
- Foster and Thrive Castor Oil 1 mg/mL Liquid NDC 70677-1085-1
- Laxative Bisacodyl 5 mg Tablet, Delayed Release NDC 70677-1086-1
- Motion Sickness Dimenhydrinate 50 mg Tablet NDC 70677-1087-1
- Motion Sickness Meclizine HCl 25 mg Tablet NDC 70677-1088-1
- Foster and Thrive Ready to Use Saline Laxative SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM and SODIUM PHOSPHATE, MONOBASIC, 7 g/118mL; 19 g/118mL Enema NDC 70677-1089-1
- Foster and Thrive Ready to Use Mineral oil Laxative 1000 g/118mL Enema NDC 70677-1090-1
- Gas Relief Simethicone 125 mg Capsule, Liquid Filled NDC 70677-1092-1
- Gas Relief Simethicone 180 mg Capsule, Liquid Filled NDC 70677-1093-1
- Stool Softener docusate sodium and sennosides 50 mg; 8.6 mg Tablet NDC 70677-1094-1
- Stool Softener Laxative Docusate Sodium 100 mg Capsule, Liquid Filled NDC 70677-1095-1
- Stool Softener Docusate Sodium 250 mg Capsule, Liquid Filled NDC 70677-1096-1
- Senna Laxative Sennosides 8.6 mg Tablet NDC 70677-1097-1
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage
⏱️ Dosage and Administration
⚠️ Warnings
📦 Storage and Handling
🧪 Active Ingredient
🧪 Inactive Ingredients
🎯 Purpose
📄 Ask a Doctor Before Use If
📄 When Using This Product
📄 Stop Use and Ask a Doctor If
🤰 If Pregnant or Breast-Feeding
📄 Keep Out of Reach of Children
🎯 Indications and Usage ▾
Uses For relief of occasional constipation and irregularity -This product generally produces bowel movement in 15 minutes to 1 hour
⏱️ Dosage and Administration ▾
Directions Adults and children 12 years of age and older Children 6 to under 12 years Children under 6 One suppository once daily 1/2 suppository once daily Ask doctor. -Detach one suppository from the strip and remove from foil - Carefully insert one suppositry well into the rectum -Do not use more than once per day
⚠️ Warnings ▾
Warnings For rectal use only.
📦 Storage and Handling ▾
Other Information do not store above 30°C (86°F)
🧪 Active Ingredient ▾
Active ingredient Bisacodyl USP, 10 mg
🧪 Inactive Ingredients ▾
Inactive Ingredients hydrogenated vegetable oil image of display
🎯 Purpose ▾
Purpose Stimulant Laxative
📄 Ask a Doctor Before Use If ▾
stomach pain, nausea or vomiting noticed a sudden change in bowel habits that persists over a period of two weeks
📄 When Using This Product ▾
When using this product May cause abdominal discomfort, faintness, rectal burning, and mild cramps
📄 Stop Use and Ask a Doctor If ▾
Stop use and ask a doctor if if you have rectal bleeding or fail to have bowel movement after using a laxative. This may indicate a serious condition you need to use a laxative for more than 1 week
🤰 If Pregnant or Breast-Feeding ▾
If pregnant or breast-feeding, ask a health professional before use.
📄 Keep Out of Reach of Children ▾
Keep out of reach of children If swallowed, get medical help or contact a Poison Control Center right away.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
207
Units reimbursed last 4 qtrs
4K
Gross reimbursed last 4 qtrs
$3.3K
Avg / prescription
$15.72
Avg / unit
$0.8097
Latest quarter Q1 2026
169Rx
Medicaid pays / ea
$0.8097
gross reimbursed
vs
NADAC / ea
$0.3197
acquisition cost
=
Spread
+$0.4900
+153% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
Fee-for-service · 175 Rx Managed care · 32 Rx
State Medicaid map
Units reimbursed · per 100k residents
2.57.7
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Bisacodyl — the ingredient across all brands.
Top reported reactions
Age at onset
Reporter sex
Male · 43%
Female · 57%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.